Genzyme/Isis Expand Mipomersen Clinical Trial Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Findings from additional mipomersen clinical trials announced by Genzyme and Isis Jan. 12 will aid in the design of a subsequent outcomes trial FDA has requested for the cholesterol-lowering drug candidate